Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Karessa has signed an agreement for manufacturing of clinical trial material for the project K-03

Karessa Pharma Holding AB announces today that an agreement for manufacture of clinical trial material has been signed between Karessa and Recipharm. The intention is to manufacture clinical trial material that will be used for Proof of Concept studies later this year.Manufacturing of clinical trial materials is a prerequisite to be able to perform clinical trials on humans. The manufacturing is performed according to GMP (Good Manufacturing Practice) to ensure that the material to be used for clinical trials have the quality required to complete the study. Karessa Pharma's

INTERIM REPORT, FIRST QUARTER OF 2017

January – March 2017 ·  The operating result for the period improved to SEK -23.2 million (-24.1), an improvement of 4 % ·  Loss after tax for the period improved to SEK -25.2 million (-25.6), an improvement of 2 % ·  Earnings per share SEK -0.43 (-0.55), an improvement of 22 % ·  Cash flow before changes in working capital improved with SEK 1.3 million to -20.15 (-21.8), an improvement of 6 % ·  Net sales for the period SEK 62,5 million (61.1), an increase of 2 % compared to same period last year  +--------------------------------------+-------+-------+---------+

Annual Report for 2016 Initiator Pharma A/S

Initiators Pharma’s Annual Report for 2016 is from today available on the company’s website, http://initiatorpharma.com/investors/financial-reports/ For further information about Initiator Pharma, please contact:   Claus Elsborg Olesen, CEOTelephone: +45 6126 0035E-mail: ceo@initiatorpharma.com About Initiator Pharma  Initiator Pharma is a pharmaceutical company based in Aarhus, Denmark, spun off from Saniona AB (listed on Nasdaq Stockholm First North Premier). The company’s primary focus is the drug candidate IPED2015 which constitutes a new treatment method for the

Interim Report Q1/2017: UPM businesses deliver a strong start for 2017

UPM-Kymmene Corporation      Interim Report          25 April 2017 at 9:50 EET Interim Report Q1/2017:UPM businesses deliver a strong start for 2017 Q1 2017 highlights · Comparable EBIT increased by 8% to EUR 305 million (281 million). · Strong operational efficiency and good growth in deliveries. · Operating cash flow was strong at EUR 396 million (341 million). · Net debt decreased to EUR 807 million (1,873 million). · UPM announced divestments of hydropower assets in Germany, Austria and the US. · UPM renewed its long-term financial targets in

Liza Nyberg – new CEO of Collector

Gothenburg, Sweden – Collector AB (publ) (Nasdaq Stockholm: COLL). Collector’s Board of Directors today appointed Liza Nyberg as the new CEO of Collector AB (publ) and Collector Bank AB.Since 2014, Liza Nyberg has been the CEO of Landshypotek Bank AB, Sweden’s ninth largest bank, where she has driven a successful process of change with digitization and a broadened product range as the foremost priorities. “It feels extremely good to have found a CEO like Liza! She combines a strong entrepreneurial drive with the experience, skills and understanding of banking operations and regulatory

Interim report January – March 2017: Good growth in all regions

·  Sales amounted to SEK 244 (187) million, corresponding to an increase of 31 percent in SEK. Net sales growth was 27 percent in local currency. ·  Operating income before depreciation and amortisation (EBITDA) amounted to SEK 95 (62) million, corresponding to a margin of 39 (33) percent. ·  Launch of RapidVit™ Omni, a media system for vitrification (rapid freezing) of eggs and embryos. ·  Net income amounted to SEK 60 (39) million, which gave earnings per share of SEK 2.73 (1.77).   Gothenburg, April 25, 2017VITROLIFE AB (publ)Thomas Axelsson, CEO

ChromoGenics sees increasing market demand and has appointed Mats Hellman as Head of Business Development

ChromoGenics is accelerating its business and partner relationships given the increasing market demand for ConverLight™ dynamic glass and solar control. Mats Hellman has been appointed Head of Business Development. Mats brings vast experience from fast growing businesses and industrial expertise to ChromoGenics.Mats has held several Vice President and General Management positions in Sweden and internationally establishing, driving and developing global businesses in multi culture environments. “We are pleased to have Mats with us to drive our business development. Mats is entrepreneurial

Moberg Pharma expands retail presence for Dermoplast

STOCKHOLM, April 25th 2017. Moberg Pharma AB (OMX: MOB) expands retail presence for a second Dermoplast® product in 7,500 CVS stores and 3,500 Walmart stores. Opening orders are expected to ship in April.Dermoplast® was acquired from Prestige Brands, Inc. in December 2016, contributing to sales and profitability as of January 2017. There are two products under the Dermoplast brand and the additional distribution means that both products are now available at all three main retailers, Walmart, Walgreens and CVS. The brand is also listed in additional drugstores, such as RiteAid, mass

Interim Report January – March 2017

CONTINUED GROWTH AND DIRECTED ISSUE OF 181 MSEKFIRST QUARTER 2017 (JAN - MAR) • Net sales of non-Durable goods in the quarter amounted to SEK 33.6 (29.1) million, corresponding to an increase of 16 percent in SEK. Sales of non-Durable goods increased by 11 percent in local currency. Net sales in the quarter amounted to SEK 37.5 (33.5) million, corresponding to an increase of 12 percent. The increase corresponds to 7 percent in local currency. The acquisition of Vivoline had a positive impact of SEK 0.9 million on sales.• Operating income before depreciation and amortization (EBITDA),

C-RAD defines definition of “major order” in the information policy

The policy change becomes effective as of the date of the present publication.About C-RAD C-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products and solutions for patient positioning, tumor localization and radiation treatment systems. All product development is conducted in three fully owned subsidiaries: C-RAD Positioning AB, C-RAD Imaging AB and C-RAD Innovation AB, all of which are located in Uppsala, Sweden. C-RAD has 48 employees. C-RAD has established three companies for direct sales: C-RAD Inc. in the US, C-RAD GmbH in Germany

Successful urban centre serves, entertains and pampers residents

YIT CORPORATION News, April 25, 2017 at 09:15 a.m.The Mall of Tripla, which is being built in Pasila, is a prime example of a shopping centre of the future. It is more than just a commercial venue – it brings its surroundings to life. Are shopping centres becoming outdated? Do consumers expect to have more than just a giant hall packed with retail space? Yes, they do, says Pirjo Aalto, Commercial Development Director. She predicts rough times for traditional shopping centres – despite the fact that it is her job to develop the Mall of Tripla in Pasila. However, the uncertain

Interim report January–March 2017

Gothenburg, Sweden – Collector AB (publ) (Nasdaq Stockholm: COLL)JANUARY – MARCH 2017 (COMPARED WITH JANUARY–MARCH 2016) · Total income increased by 28%, amounting to SEK 438 million (344) · Earnings after tax (EAT) increased by 34%, amounting to SEK 113 million (85) · Return on equity (RoE) was 20% (21) · Earnings per share increased to SEK 1.11 (0.86) · Continued strong growth with increased quality in the credit portfolio, SEK 14,973 million (9,618) +56% · Positive development in credit losses 1.1% (1.3) · As of January 2, 2017 Collector moved up to Nasdaq

Ahlsell acquires Svensk Industri & Kommunservice AB

Ahlsell has signed an agreement to acquire all shares in Svensk Industri & Kommunservice AB. The company has a turnover of approximately SEK 55 million and has 13 employees.Svensk Industri & Kommunservice AB, known in the market under the brand of Sikab, is one of Gothenburg's leading companies within professional workwear and footwear. The company has a 1,200 square meter store on Hisingen near the Tingstad Tunnel, where approximately 5,000 warehouse articles are offered to municipalities and small and medium-sized entrepreneurs. "Sikab has an attractive customer base with many

New date for publishing of Eltel’s first quarter 2017 interim report

Eltel will publish its first quarter 2017 interim report on Tuesday 2 May 2017 after the stock market closure, instead of on 5 May 2017.Eltel’s CEO Håkan Kirstein and interim CFO Lars Nilsson will host a presentation via audiocast in English on Wednesday 3 May 2017 starting at 8.00 am CET. The presentation will be audiocasted live on www.eltelgroup.com. For those who would like to participate on the telephone conference in connection with the presentation, the telephone numbers are: · SE: +46 8 56 64 26 92 · FI: +358 9 81 71 04 92 · UK: +44 20 30 08 98 03 Please, call in

Invitation to presentation of Recipharm’s interim report for the first quarter 2017 on the 27th April

Recipharm will publish its interim report for January-March 2017 on 27 April at 07:45 am CET.The company invites investors, analysts and media to a web conference (in English) on 27 April at 09:30 am CET, where CEO and CFO will present and comment on the report as well as answer questions. The report will be available on Recipharm’s website www.recipharm.com/investor-relations from 07:45 am CET the same day and the presentation from the webcast will be uploaded during the day on the 27 April. To participate in the web conference, please use the below link: http://edge.media-server.

Interim Report January–March 2017

SBAB’s Interim Report January–March 2017 is now available for download on www.sbab.se/IR. CEO statement from Klas Danielsson: We continue to robustly develop operations. High growth in both deposits and lending was posted in the first quarter of the year, and we delivered strong results. Our robust market position together with a strengthened offering in two-year fixed-interest mortgages resulted in new lending for the period of SEK 18.0 billion. At the end of the quarter, SBAB’s total lending

Proact buys back own shares

The Annual General Meeting held on 2 May 2016 authorised the Board of Directors at Proact IT Group AB to implement a buyback of own shares amounting to a maximum of 10 per cent of the total number of outstanding shares. According to a press release published on 19 July 2016, Proact’s Board has made a decision to buy back the company’s own shares. As at 24 April 2017, a total of 77,900 shares have been bought back, at an average price of SEK 192.50 per share. With this, a total of 238,525 shares have been bought back since the Annual General Meeting, a figure equivalent to 2.6 per cent of

CXENSE ASA - ANNUAL REPORT 2016

OSLO, NORWAY - APRIL 25, 2017 - CXENSE ASA (OSE:CXENSE) TODAY PUBLISHED ITS ANNUAL REPORT FOR THE YEAR ENDED DECEMBER 31, 2016.Highlights: Cxense develops the world’s leading personalization and data management software. The Cxense software enables businesses to gather, analyze and act on data to increase conversion and revenue across all digital platforms. The digital economy is growing, with real-time data management and personalization as a key driver for reaching the online audience on all digital surfaces. Important steps were taken in 2016 to position Cxense for the

Interim report January-March 2017: Continued strong development in the insurance market

· Continued strong organic growth · Moving into new diagnostic areas · Increased capacity in existing premises enables continued expansion Events after end of the reporting period · Trygg-Hansa and GHP in collaboration regarding health care planning First quarter 2017  · Sales revenues increased to SEK 260.8 million (231.5)  · Organic growth amounted to 11.0 percent (5.9)  · EBITDA amounted to SEK 18.2 million (18.1)  · EBITDA margin amounted to 7.0 percent (7.8)  · Result after tax (EAT) amounted to SEK 8.2 million (9.4)  · Result per share amounted to

SciBase publishes the Annual report for 2016

SciBase hereby announces that the Annual report for 2016 is available at the Company’s website www.scibase.com.A pdf-version of the annual report is enclosed to this press-release. A printed version of the Annual report will only be distributed to shareholders who actively request a printed copy. For more information, please contact: Michael Colérus, CFOTel: +46 70 341 34 72 E-mail: michael.colerus@scibase.com This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for

Wilson Therapeutics presents promising neurological Phase 2 data for WTX101 at AAN meeting

Wilson Therapeutics AB (publ), announced today a poster presentation at the 69th American Academy of Neurology (AAN) Annual Meeting in Boston, MA, 22-28 April, 2017, highlighting the results on neurological parameters from the recently completed Phase 2 trial of WTX101 (bis-choline tetrathiomolybdate), an investigational first-in-class copper modulating agent with a unique mode of action for the treatment of patients with Wilson Disease.WTX101-201 was a 24-week open-label Phase 2 study evaluating the efficacy and safety of WTX101 monotherapy in 28 newly-diagnosed adult patients with

TECHSTEP – CONTRACT ANNOUNCEMENT

On 24 April, Nordialog Oslo AS, a company owned by Techstep ASA  (“Techstep”) entered into an agreement with Norsk Sykepleierforbund  for delivery of mobile-as-a-service of 2650 Apple iPads. The agreement includes buy-back of current devices as well as financing through Techstep Finance AS (a joint venture between Techstep and Bridge Capital AS), and a newly developed mobile asset management solution provided by Mytos AS (a software-as-a-service company owned by Techstep). Training of resources, support and handling of privacy issues are also part of the contract. Gaute Engbakk, CEO of

There are no items matching the current filter
There are no more items matching the current filter
Back to top